Bloem BR, Okun MS, Klein C. Parkinson’s illness. The Lancet. 2021;397:2284–303.
Ovallath S, Deepa P. The historical past of parkinsonism: descriptions in historic Indian medical literature. Mov Disord. 2013;28:566–8.
Parkinson J. An Essay on the Shaking Palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223–36.
Goetz CG. The historical past of Parkinson’s illness: early medical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862–a008862.
Nussbaum RL, Ellis CE. Alzheimer’s illness and Parkinson’s illness. N Engl J Med. 2003;348:1356–64.
Collaborators GN. Global, regional, and nationwide burden of neurological issues, 1990–2016: a scientific evaluation for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–80.
Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A potential examine of familial versus sporadic Parkinson’s illness. Neurodegener Dis. 2007;4:424–7.
Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici Ok. Stages within the growth of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–34.
Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson’s illness pathogenesis. Mol Neurodegener. 2019;14:35.
Sveinbjornsdottir S. The medical signs of Parkinson’s illness. J Neurochem. 2016;139:318–24.
Cheng HC, Ulane CM, Burke RE. Clinical development in Parkinson illness and the neurobiology of axons. Ann Neurol. 2010;67:715–25.
Braak H, Bohl JR, Müller CM, Rüb U, de Vos RAI, Del Tredici Ok. Stanley Fahn Lecture 2005: The staging process for the inclusion physique pathology related to sporadic Parkinson’s illness reconsidered. Mov Disord. 2006;21:2042–51.
Poewe W, Seppi Ok, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE. Parkinson illness. Nat Rev Dis Primers. 2017;3:17013.
Jankovic J. Parkinson’s illness: medical options and prognosis. J Neurol Neurosurg Psychiatry. 2008;79:368–76.
Solari N, Bonito-Oliva A, Fisone G, Brambilla R. Understanding cognitive deficits in Parkinson’s illness: classes from preclinical animal fashions. Learn Mem. 2013;20:592–600.
Schneider F, Althaus A, Backes V, Dodel R. Psychiatric signs in Parkinson’s illness. Eur Arch Psychiatry Clin Neurosci. 2008;258:55–9.
Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s illness Clin Med (Lond). 2016;16:371–5.
Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM. Mitochondria within the etiology and pathogenesis of parkinson’s illness. Ann Neurol. 1998;44:S89–98.
Park J-S, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21.
Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s illness. Neurology. 1996;47:161S.
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson’s illness. Front Neuroanatomy. 2015;9:91.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s illness: a goal for neuroprotection? The Lancet Neurology. 2009;8:382–97.
Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s illness and its potential as therapeutic goal. Transl Neurodegener. 2015;4:19.
Ambrosi G, Cerri S, Blandini F. An additional replace on the position of excitotoxicity within the pathogenesis of Parkinson’s illness. J Neural Transm (Vienna, Austria : 1996). 2014;121:849–59.
van der Brug MP, Singleton A, Gasser T, Lewis PA. Parkinson’s illness: From human genetics to medical trials. Sci Transl Med. 2015;7:205ps220.
Funayama M, Nishioka Ok, Li Y, Hattori N. Molecular genetics of Parkinson’s illness: Contributions and international traits. J Hum Genet. 2022. https://doi.org/10.1038/s10038-022-01058-5.
McNaught KS, Olanow CW. Protein aggregation within the pathogenesis of familial and sporadic Parkinson’s illness. Neurobiol Aging. 2006;27:530–45.
Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer’s Pathology in Parkinson’s Disease Dementia. Mov Disord Clin Pract. 2016;3:367–75.
Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative harm in cells and in vivo. Nat Metab. 2022;4:651–62.
Chaudhuri KR, Schapira AH. Non-motor signs of Parkinson’s illness: dopaminergic pathophysiology and therapy. Lancet Neurol. 2009;8:464–74.
Braak H, Braak E. Pathoanatomy of Parkinson’s illness. J Neurol. 2000;247:II3–10.
Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of present Parkinson’s illness remedy. Ann Neurol. 2003;53(Suppl 3):S3-12; dialogue S12-5.
Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548–60.
Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field. Ann Neurol. 2021;90:711–9.
Nerella SG, Singh P, Sanam T, Digwal CS. PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective. Front Med (Lausanne). 2022;9:812270.
Lu FM, Yuan Z. PET/SPECT molecular imaging in medical neuroscience: latest advances within the investigation of CNS illnesses. Quant Imaging Med Surg. 2015;5:433–47.
Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501–16.
Zhu L, Ploessl Ok, Kung HF. PET/SPECT imaging brokers for neurodegenerative illnesses. Chem Soc Rev. 2014;43:6683–91.
Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson’s illness. Biochem Biophys Acta. 2009;1792:722–9.
Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson’s disease-related sample as a biomarker for medical trials in early stage illness. Neuroimage Clin. 2018;20:572–9.
Meyer PT, Frings L, Rücker G, Hellwig S. (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017;58:1888–98.
Garraux G, Phillips C, Schrouff J, Kreisler A, Lemaire C, Degueldre C, Delcour C, Hustinx R, Luxen A, Destée A, Salmon E. Multiclass classification of FDG PET scans for the excellence between Parkinson’s illness and atypical parkinsonian syndromes. Neuroimage Clin. 2013;2:883–93.
Mudali D, Teune LK, Renken RJ, Leenders KL, Roerdink JB. Classification of Parkinsonian syndromes from FDG-PET mind information utilizing resolution bushes with SSM/PCA options. Comput Math Methods Med. 2015;2015:136921.
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, et al. Large-scale meta-analysis of genome-wide affiliation information identifies six new danger loci for Parkinson’s illness. Nat Genet. 2014;46:989–93.
Wassouf Z, Schulze-Hentrich JM. Alpha-synuclein on the nexus of genes and atmosphere: the influence of environmental enrichment and stress on mind well being and illness. J Neurochem. 2019;150:591–604.
Goedert M. Alpha-synuclein and neurodegenerative illnesses. Nat Rev Neurosci. 2001;2:492–501.
Vekrellis Ok, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of α-synuclein in neurological issues. Lancet Neurol. 2011;10:1015–25.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy our bodies. Nature. 1997;388:839–40.
Wakabayashi Ok, Tanji Ok, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders. Mol Neurobiol. 2013;47:495–508.
Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha synuclein to neuronal survival and performance – Implications for Parkinson’s illness. J Neurochem. 2016;137:331–59.
Polymeropoulos MH. Mutation within the -Synuclein Gene Identified in Families with Parkinson’s Disease. Science. 1997;276:2045–7.
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. Ala30Pro mutation within the gene encoding alpha-synuclein in Parkinson’s illness. Nat Genet. 1998;18:106–8.
Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, et al. The new mutation, E46K, of α-synuclein causes parkinson and Lewy physique dementia. Ann Neurol. 2004;55:164–73.
Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s illness. Mov Disord. 2013;28:811–3.
Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, et al. α-Synucleinopathy related to G51D SNCA mutation: a hyperlink between Parkinson’s illness and a number of system atrophy? Acta Neuropathol. 2013;125:753–69.
Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Pöyhönen M, Paetau A. A novel α-synuclein mutation A53E related to atypical a number of system atrophy and Parkinson’s disease-type pathology. Neurobiol Aging. 2014;35:2180.e2181-2180.e2185.
Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, Pieri L, Madiona Ok, Dürr A, Melki R, et al. G51D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73:459–71.
Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel α-synuclein missense mutation in Parkinson illness. Neurology. 2013;80:1062.
Phillipson OT. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium visitors, & circadian dysfunction in Parkinson’s illness. An built-in technique for administration. Ageing Res Rev. 2017;40:149–67.
Yoshino H, Hirano M, Stoessl AJ, Imamichi Y, Ikeda A, Li Y, Funayama M, Yamada I, Nakamura Y, Sossi V, et al. Homozygous alpha-synuclein p.A53V in familial Parkinson’s illness. Neurobiol Aging. 2017;57(248):e247-248 e212.
Chavarría C, Souza JM. Oxidation and nitration of α-synuclein and their implications in neurodegenerative illnesses. Arch Biochem Biophys. 2013;533:25–32.
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a brand new type of alpha-synuclein by parkin from human mind: implications for Parkinson’s illness. Science. 2001;293:263–9.
Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, et al. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions. J Neurosci. 2010;30:3184–98.
Shah M, Seibyl J, Cartier A, Bhatt R, Catafau AM. Molecular imaging insights into neurodegeneration: concentrate on alpha-synuclein radiotracers. J Nucl Med. 2014;55:1397–400.
Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. In vitro excessive affinity alpha-synuclein binding websites for the amyloid imaging agent PIB will not be matched by binding to Lewy our bodies in postmortem human mind. J Neurochem. 2008;105:1428–37.
Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez Ok, Cortes M, Culvenor JG, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy our bodies. J Neurosci. 2007;27:10365–71.
Levigoureux E, Lancelot S, Bouillot C, Chauveau F, Verdurand M, Verchere J, Billard T, Baron T, Zimmer L. Binding of the PET radiotracer [(1)(8)F]BF227 doesn’t mirror the presence of alpha-synuclein aggregates in transgenic mice. Curr Alzheimer Res. 2014;11:955–60.
Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai Ok, Villemagne VL. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy our bodies. Eur J Pharmacol. 2009;617:54–8.
Yu L, Cui J, Padakanti PK, Engel L, Bagchi DP, Kotzbauer PT, Tu Z. Synthesis and in vitro analysis of alpha-synuclein ligands. Bioorg Med Chem. 2012;20:4625–34.
Bagchi DP, Yu L, Perlmutter JS, Xu J, Mach RH, Tu Z, Kotzbauer PT. Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent. PLoS ONE. 2013;8(2):e55031.
Zhang X, Jin H, Padakanti P, Li J, Yang H, Fan J, Mach R, Kotzbauer P, Tu Z. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein. Appl Sci. 2014;4(1):66–78.
Ferrie JJ, Lengyel-Zhand Z, Janssen B, Lougee MG, Giannakoulias S, Hsieh CJ, Pagar VV, Weng CC, Xu H, Graham TJA, et al. Identification of a nanomolar affinity alpha-synuclein fibril imaging probe by ultra-high throughput in silico screening. Chem Sci. 2020;11:12746–54.
Miranda-Azpiazu P, Svedberg M, Higuchi M, Ono M, Jia Z, Sunnemark D, Elmore CS, Schou M, Varrone A. Identification and in vitro characterization of C05–01, a PBB3 spinoff with improved affinity for alpha-synuclein. Brain Res. 2020;1749:147131.
Chen YF, Bian J, Zhang P, Bu LL, Shen Y, Yu WB, Lu XH, Lin X, Ye DY, Wang J, Chu Y. Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for alpha-synuclein fibrils by SPR analysis system. Bioorg Med Chem. 2020;28:115358.
Kaide S, Watanabe H, Shimizu Y, Iikuni S, Nakamoto Y, Hasegawa M, Itoh Ok, Ono M. Identification and Evaluation of Bisquinoline Scaffold as a New Candidate for alpha-Synuclein-PET Imaging. ACS Chem Neurosci. 2020;11:4254–61.
Kuebler L, Buss S, Leonov A, Ryazanov S, Schmidt F, Maurer A, Weckbecker D, Landau AM, Lillethorup TP, Bleher D, et al. [(11)C]MODAG-001-towards a PET tracer concentrating on alpha-synuclein aggregates. Eur J Nucl Med Mol Imaging. 2021;48:1759–72.
Matsuoka Ok, Ono M, Takado Y, Hirata Ok, Endo H, Ohfusa T, Kojima T, Yamamoto T, Onishi T, Orihara A, et al. High-Contrast Imaging of α-Synuclein Pathologies in Living Patients with Multiple System Atrophy. Movement Disorders. 2022;37(10):2159–61. https://doi.org/10.1002/mds.29186.
Capotosti F, Vokali E, Molette J, Ravache M, Delgado C, Kocher J, Pittet L, Dimitrakopoulos IK, Di-Bonaventura I, Touilloux T, et al. The growth of [18F]ACI-12589, a excessive affinity and selective alpha-synuclein radiotracer, as a biomarker for Parkinson’s illness and different synucleinopathies. Alzheimers Dement. 2021;17:e053943.
Roshanbin S, Xiong M, Hultqvist G, Söderberg L, Zachrisson O, Meier S, Ekmark-Lewén S, Bergström J, Ingelsson M, Sehlin D, Syvänen S. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208:108985.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio Ok, Iwatsubo T. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160–4.
Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s illness dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14:626–36.
Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, Van den Haute C, Gentleman S, Melki R, Baekelandt V. The structural variations between patient-derived α-synuclein strains dictate traits of Parkinson’s illness, a number of system atrophy and dementia with Lewy our bodies. Acta Neuropathol. 2020;139:977–1000.
McKeith IG, Galasko D, Kosaka Ok, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, et al. Consensus tips for the medical and pathologic prognosis of dementia with Lewy our bodies (DLB): report of the consortium on DLB worldwide workshop. Neurology. 1996;47:1113–24.
Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, et al. DLB and PDD boundary points: prognosis, therapy, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.
van Rumund A, Green AJE, Fairfoul G, Esselink RAJ, Bloem BR, Verbeek MM. α-Synuclein real-time quaking-induced conversion within the cerebrospinal fluid of unsure instances of parkinsonism. Ann Neurol. 2019;85:777–81.
Iranzo A, Fairfoul G, Ayudhaya ACN, Serradell M, Gelpi E, Vilaseca I, Sanchez-Valle R, Gaig C, Santamaria J, Tolosa E, et al. Detection of α-synuclein in CSF by RT-QuIC in sufferers with remoted rapid-eye-movement sleep behaviour dysfunction: a longitudinal observational examine. Lancet Neurol. 2021;20:203–12.
Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG. The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017;76:2–15.
Antelmi E, Donadio V, Incensi A, Plazzi G, Liguori R. Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep conduct dysfunction. Neurology. 2017;88:2128–31.
Donadio V, Incensi A, Piccinini C, Cortelli P, Giannoccaro MP, Baruzzi A, Liguori R. Skin nerve misfolded α-synuclein in pure autonomic failure and Parkinson illness. Ann Neurol. 2016;79:306–16.
Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Stanzani Maserati M, Devigili G, Eleopra R, Defazio G, Montini F, et al. A brand new potential biomarker for dementia with Lewy our bodies: Skin nerve α-synuclein deposits. Neurology. 2017;89:318–26.
Gibbons CH, Garcia J, Wang N, Shih LC, Freeman R. The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson illness. Neurology. 2016;87:505–12.
Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D. The Systemic Synuclein Sampling Study: towards a biomarker for Parkinson’s illness. Biomark Med. 2017;11:359–68.
Wang Z, Becker Ok, Donadio V, Siedlak S, Yuan J, Rezaee M, Incensi A, Kuzkina A, Orrú CD, Tatsuoka C, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020;78:1–11.
Donadio V, Doppler Ok, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, et al. Abnormal α-synuclein deposits in pores and skin nerves: intra- and inter-laboratory reproducibility. Eur J Neurol. 2019;26:1245–51.
Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease. Front Mol Neurosci. 2019;12:299–299.
Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, Bohn MC. Silencing of human alpha-synuclein in vitro and in rat mind utilizing lentiviral-mediated RNAi. Exp Neurol. 2006;198:382–90.
Takahashi M, Suzuki M, Fukuoka M, Fujikake N, Watanabe S, Murata M, Wada Ok, Nagai Y, Hohjoh H. Normalization of Overexpressed α-Synuclein Causing Parkinson’s Disease By a Moderate Gene Silencing With RNA Interference. Molecular Therapy – Nucleic Acids. 2015;4:e241.
Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, Lincoln S, Braithwaite A, He Z, Ogholikhan S, Hinkle Ok, et al. In vivo silencing of alpha-synuclein utilizing bare siRNA. Mol Neurodegener. 2008;3:19.
Mittal S, Bjørnevik Ok, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, et al. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving danger of Parkinson’s illness. Science. 2017;357:891–8.
Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem. 2004;279:25497–502.
Cox D, Selig E, Griffin MDW, Carver JA, Ecroyd H. Small Heat-shock Proteins Prevent α-Synuclein Aggregation through Transient Interactions and Their Efficacy Is Affected by the Rate of Aggregation. J Biol Chem. 2016;291:22618–29.
Ghochikyan A, Petrushina I, Davtyan H, Hovakimyan A, Saing T, Davtyan A, Cribbs DH, Agadjanyan MG. Immunogenicity of epitope vaccines concentrating on completely different B cell antigenic determinants of human α-synuclein: Feasibility examine. Neurosci Lett. 2014;560:86–91.
Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, et al. Effects of alpha-synuclein immunization in a mouse mannequin of Parkinson’s illness. Neuron. 2005;46:857–68.
Sanchez-Guajardo V, Annibali A, Jensen PH, Romero-Ramos M. alpha-Synuclein vaccination prevents the buildup of parkinson disease-like pathologic inclusions in striatum in affiliation with regulatory T cell recruitment in a rat mannequin. J Neuropathol Exp Neurol. 2013;72:624–45.
Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi Ok, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic mannequin of Lewy physique illness. PLoS ONE. 2011;6:e19338.
Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG. First-in-human evaluation of PRX002, an anti-alpha-synuclein monoclonal antibody, in wholesome volunteers. Mov Disord. 2017;32:211–8.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek Ok, Postuma RB, Pavese N, Stocchi F, Azulay JP, et al. Trial of Prasinezumab in Early-Stage Parkinson’s Disease. N Engl J Med. 2022;387:421–32.
Fjord-Larsen L, Thougaard A, Wegener KM, Christiansen J, Larsen F, Schrøder-Hansen LM, Kaarde M, Ditlevsen DK. Nonclinical security analysis, pharmacokinetics, and goal engagement of Lu AF82422, a monoclonal IgG1 antibody towards alpha-synuclein in growth for therapy of synucleinopathies. MAbs. 2021;13:1994690.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s illness. Nature. 2016;537:50–6.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388:9–21.
Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA, Baeriswyl JL, Cavegn N, Senn L, Su L, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates illness phenotypes in Parkinson’s illness fashions. Neurobiol Dis. 2019;124:276–88.
Lindström V, Fagerqvist T, Nordström E, Eriksson F, Lord A, Tucker S, Andersson J, Johannesson M, Schell H, Kahle PJ, et al. Immunotherapy concentrating on α-synuclein protofibrils decreased pathology in (Thy-1)-h[A30P] α-synuclein mice. Neurobiol Dis. 2014;69:134–43.
Nordström E, Eriksson F, Sigvardson J, Johannesson M, Kasrayan A, Jones-Kostalla M, Appelkvist P, Söderberg L, Nygren P, Blom M, et al. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse fashions of Parkinson’s illness. Neurobiol Dis. 2021;161:105543.
Chen SW, Drakulic S, Deas E, Ouberai M, Aprile FA, Arranz R, Ness S, Roodveldt C, Guilliams T, De-Genst EJ, et al. Structural characterization of poisonous oligomers which can be kinetically trapped throughout α-synuclein fibril formation. Proc Natl Acad Sci USA. 2015;112:E1994-2003.
Vaikath NN, Hmila I, Gupta V, Erskine D, Ingelsson M, El-Agnaf OMA. Antibodies towards alpha-synuclein: instruments and therapies. J Neurochem. 2019;150:612–25.
Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, et al. Brain supply of therapeutic proteins utilizing an Fc fragment blood-brain barrier transport automobile in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359.
Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, Bergström J, Ingelsson M, Syvänen S, Sehlin D. Reduction of αSYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody. Pharmaceutics. 2022;14(7):1412.
Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in people as a result of a product of meperidine-analog synthesis. Science. 1983;219:979–80.
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate mannequin of parkinsonism: selective destruction of dopaminergic neurons within the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA. 1983;80:4546–50.
Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) within the squirrel monkey. Brain Res. 1984;292:390–4.
Schneider JS, Denaro FJ. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse mind. J Neuropathol Exp Neurol. 1988;47:452–8.
Sayre LM. Biochemical mechanism of motion of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett. 1989;48:121–49.
Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and associated compounds. J Neurochem. 1993;61:1191–206.
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complicated I deficiency in Parkinson’s illness. J Neurochem. 1990;54:823–7.
Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson’s Disease. IUBMB Life. 2001;52:135–41.
Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative illnesses. Biochem Biophys Acta. 2010;1802:135–42.
Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson illness pathogenesis. Nat Clin Pract Neurol. 2008;4:600–9.
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative illnesses. Nature. 2006;443:787–95.
Bose A, Beal MF. Mitochondrial dysfunction in Parkinson’s illness. J Neurochem. 2016;139(Suppl 1):216–31.
Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a evaluation. Neurotox Res. 2000;1:181–95.
Mansur A, Comley R, Lewis Y, Middleton L, Huiban M, Guo Q, Passchier J, Tsukada H, Gunn R, Rabiner E. MIND MAPS CONSORTIUM ft: <sturdy>Imaging of Mitochondrial Complex 1 with <sup>18</sup>F-BCPP-EF within the Healthy Human Brain</sturdy>. J Nucl Med. 2018;59:1709–1709.
Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II security and medical comparability with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery illness: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469–77.
Bengs S, Warnock GI, Portmann A, Mikail N, Rossi A, Ahmed H, Etter D, Treyer V, Gisler L, Pfister SK, et al. Rest/stress myocardial perfusion imaging by positron emission tomography with (18)F-Flurpiridaz: A feasibility examine in mice. J Nucl Cardiol. 2022. https://doi.org/10.1007/s12350-022-02968-9.
Haider A, Bengs S, Portmann A, Rossi A, Ahmed H, Etter D, Warnock GI, Mikail N, Grämer M, Meisel A, et al. Role of intercourse hormones in modulating myocardial perfusion and coronary movement reserve. Eur J Nucl Med Mol Imaging. 2022;49:2209–18.
Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET examine. Ann Neurol. 2002;52:849–53.
Gan-Or Z, Liong C, Alcalay RN. GBA-Associated Parkinson’s Disease and Other Synucleinopathies. Curr Neurol Neurosci Rep. 2018;18:44.
Choi JH, Stubblefield B, Cookson MR, Goldin E, Velayati A, Tayebi N, Sidransky E. Aggregation of alpha-synuclein in mind samples from topics with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185–8.
Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher illness glucocerebrosidase and alpha-synuclein type a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37–52.
Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol results in glucocerebrosidase and alpha-synuclein transgenic mice. Ann Neurol. 2016;80:766–75.
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. Mutations in LRRK2 trigger autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7.
Chen J, Chen Y, Pu J. Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic Target. Eur Neurol. 2018;79:256–65.
Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, et al. Synthesis and Preliminary Evaluation of [(11) C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson’s Disease. ChemMedChem. 2019;14:1580–5.
Malik N, Kornelsen R, McCormick S, Colpo N, Merkens H, Bendre S, Benard F, Sossi V, Schirrmacher R, Schaffer P. Development and organic analysis of[(18)F]FMN3PA & [(18)F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. Eur J Med Chem. 2021;211:113005.
Rideout HJ, Chartier-Harlin MC, Fell MJ, Hirst WD, Huntwork-Rodriguez S, Leyns CEG, Mabrouk OS, Taymans JM. The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson’s Disease. Front Neurosci. 2020;14:865.
Chen Z, Chen J, Chen L, Yoo C-H, Rong J, Fu H, Shao T, Coffman Ok, Steyn SJ, Davenport AT, et al: Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand. J Med Chem. 2022.
Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson illness: challenges of medical trials. Nat Rev Neurol. 2020;16:97–107.
Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, et al. Leucine-rich repeat kinase 2 regulates the development of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron. 2009;64:807–27.
Cookson MR. The position of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s illness. Nat Rev Neurosci. 2010;11:791–7.
Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, Andersen SL, Stephens RM, Benes FM, Sonntag KC. Gene expression profiling of substantia nigra dopamine neurons: additional insights into Parkinson’s illness pathology. Brain. 2009;132:1795–809.
Manzoni C, Lewis PA. LRRK2 and Autophagy. Adv Neurobiol. 2017;14:89–105.
Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, et al: Preclinical and medical analysis of the LRRK2 inhibitor DNL201 for Parkinson’s illness. Sci Transl Med. 2022;14:eabj2658.
West AB. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson illness. Exp Neurol. 2017;298:236–45.
Zhao HT, John N, Delic V, Ikeda-Lee Ok, Kim A, Weihofen A, Swayze EE, Kordasiewicz HB, West AB, Volpicelli-Daley LA. LRRK2 Antisense Oligonucleotides Ameliorate alpha-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model. Mol Therapy Nucleic Acids. 2017;8:508–19.
Ntetsika T, Papathoma PE, Markaki I. Novel focused therapies for Parkinson’s illness. Mol Med. 2021;27:17.
Lee JY, Koga H, Kawaguchi Y, Tang W, Wong E, Gao YS, Pandey UB, Kaushik S, Tresse E, Lu J, et al. HDAC6 controls autophagosome maturation important for ubiquitin-selective quality-control autophagy. Embo j. 2010;29:969–80.
Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, Nedelsky NB, Schwartz SL, DiProspero NA, Knight MA, Schuldiner O, et al. HDAC6 rescues neurodegeneration and gives an important hyperlink between autophagy and the UPS. Nature. 2007;447:860–4.
Simões-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a goal for neurodegenerative illnesses: what makes it completely different from the opposite HDACs? Mol Neurodegener. 2013;8:7.
Koole M, Van Weehaeghe D, Serdons Ok, Herbots M, Cawthorne C, Celen S, Schroeder FA, Hooker JM, Bormans G, de Hoon J, et al. Clinical validation of the novel HDAC6 radiotracer [(18)F]EKZ-001 within the human mind. Eur J Nucl Med Mol Imaging. 2021;48:596–611.
Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu Ok, Przedborski S. The position of glial cells in Parkinson’s illness. Curr Opin Neurol. 2001;14:483–9.
Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory response following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol. 1999;156:50–61.
Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia within the central nervous system illnesses. Mol Neurobiol. 2014;49:1422–34.
Nayak D, Roth TL, McGavern DB. Microglia growth and performance. Annu Rev Immunol. 2014;32:367–402.
Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. Translocator protein (18 okDa) (TSPO) as a therapeutic goal for neurological and psychiatric issues. Nat Rev Drug Discovery. 2010;9:971–88.
Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80:308–22.
Brooks DJ. Technology Insight: imaging neurodegeneration in Parkinson’s illness. Nat Clin Pract Neurol. 2008;4:267–77.
Imamura Ok, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of main histocompatibility complicated class II-positive microglia and cytokine profile of Parkinson’s illness brains. Acta Neuropathol. 2003;106:518–26.
Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL. [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory therapy in Parkinson’s illness? Parkinsonism Relat Disord. 2010;16:57–9.
Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert Ok, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s illness. Neurobiol Dis. 2006;21:404–12.
Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson’s illness. Ann Neurol. 2005;57:168–75.
Kobylecki C, Counsell SJ, Cabanel N, Wächter T, Turkheimer FE, Eggert Ok, Oertel W, Brooks DJ, Gerhard A. Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism Relat Disord. 2013;19:527–32.
Chauveau F, Van Camp N, Dolle F, Kuhnast B, Hinnen F, Damont A, Boutin H, James M, Kassiou M, Tavitian B. Comparative analysis of the translocator protein radioligands 11C-DPA-713, 18F-DPA-714, and 11C-PK11195 in a rat mannequin of acute neuroinflammation. J Nucl Med. 2009;50:468–76.
Zhang M-R, Maeda J, Furutsuka Ok, Yoshida Y, Ogawa M, Suhara T, Suzuki Ok. [18F]FMDAA1106 and [18F]FEDAA1106: two positron-Emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett. 2003;13:201–4.
Zhang M-R, Kida T, Noguchi J, Furutsuka Ok, Maeda J, Suhara T, Suzuki Ok. [11C]DAA1106: radiosynthesis and in vivo binding to peripheral benzodiazepine receptors in mouse mind. Nucl Med Biol. 2003;30:513–9.
Maeda J, Suhara T, Zhang MR, Okauchi T, Yasuno F, Ikoma Y, Inaji M, Nagai Y, Takano A, Obayashi S, Suzuki Ok. Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging device for glial cells within the mind. Synapse. 2004;52:283–91.
Yui J, Hatori A, Kawamura Ok, Yanamoto Ok, Yamasaki T, Ogawa M, Yoshida Y, Kumata Ok, Fujinaga M, Nengaki N, et al. Visualization of early infarction in rat mind after ischemia utilizing a translocator protein (18 okDa) PET ligand [11C]DAC with ultra-high particular exercise. Neuroimage. 2011;54:123–30.
Gulyas B, Toth M, Vas A, Shchukin E, Kostulas Ok, Hillert J, Halldin C. Visualising neuroinflammation in post-stroke sufferers: a comparative PET examine with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. Curr Radiopharm. 2012;5:19–28.
Brody AL, Gehlbach D, Garcia LY, Enoki R, Hoh C, Vera D, Kotta KK, London ED, Okita Ok, Nurmi EL, et al. Effect of in a single day smoking abstinence on a marker for microglial activation: a [(11)C]DAA1106 positron emission tomography examine. Psychopharmacology. 2018;235:3525–34.
Best L, Ghadery C, Pavese N, Tai YF, Strafella AP. New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease. Curr Neurol Neurosci Rep. 2019;19:24.
Zhang L, Hu Ok, Shao T, Hou L, Zhang S, Ye W, Josephson L, Meyer JH, Zhang MR, Vasdev N, et al. Recent developments on PET radiotracers for TSPO and their functions in neuroimaging. Acta pharmaceutica Sinica B. 2021;11:373–93.
Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M, Böning G, Ertl-Wagner B, Kümpfel T, Milenkovic VM, et al. TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in sufferers with relapsing–remitting a number of sclerosis. Eur J Nucl Med Mol Imaging. 2018;45:1423–31.
Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore J, O’Shea D, Wynn D, Morisson-Iveson V, Ewan A, et al. [18F]GE-180: a novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 okDa (TSPO). Bioorg Med Chem Lett. 2012;22:1308–13.
Alam MM, Lee J, Lee SY. Recent Progress within the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases. Nucl Med Mol Imaging. 2017;51:283–96.
Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB. 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med. 2017;58:320–5.
Siméon FG, Lee J-H, Morse CL, Stukes I, Zoghbi SS, Manly LS, Liow J-S, Gladding RL, Dick RM, Yan X, et al. Synthesis and Screening in Mice of Fluorine-Containing PET Radioligands for TSPO: Discovery of a Promising 18F-Labeled Ligand. J Med Chem. 2021;64:16731–45.
Athauda D, Maclagan Ok, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury Ok, Hibbert S, Budnik N, Zampedri L, Dickson J, et al. Exenatide as soon as weekly versus placebo in Parkinson’s illness: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–75.
Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson illness. Nat Rev Immunol. 2022;22(11):657–73.
Fujimoto H, Fujita N, Hamamatsu Ok, Murakami T, Nakamoto Y, Saga T, Ishimori T, Shimizu Y, Watanabe H, Sano Ok, et al. First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [(18)F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas. Front Endocrinol (Lausanne). 2021;12:717101.
Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, Kiesewetter DO, Zhu Z, Li F, Zhao Y, Chen X. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. J Nucl Med. 2016;57:715–20.
Antwi Ok, Fani M, Nicolas G, Rottenburger C, Heye T, Reubi JC, Gloor B, Christ E, Wild D. Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study. J Nucl Med. 2015;56:1075–8.
Liu Y, Liu S, Liu L, Gong X, Liu J, Sun L, Liu X, Wu L, Chen L, Wang L, et al. Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. Rheumatol Ther. 2022;9:175–89.
Tobinick EL, Chen Ok, Chen X. Rapid intracerebroventricular supply of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes. 2009;2:28.
Colonna M. TREMs within the immune system and past. Nat Rev Immunol. 2003;3:445–53.
Guo Y, Wei X, Yan H, Qin Y, Yan S, Liu J, Zhao Y, Jiang F, Lou H. TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson’s illness fashions. Faseb j. 2019;33:12164–74.
Wilson EN, Swarovski MS, Linortner P, Shahid M, Zuckerman AJ, Wang Q, Channappa D, Minhas PS, Mhatre SD, Plowey ED, et al. Soluble TREM2 is elevated in Parkinson’s illness subgroups with elevated CSF tau. Brain. 2020;143:932–43.
Meier SR, Sehlin D, Hultqvist G, Syvänen S. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer’s Disease. Mol Imaging Biol. 2021;23:665–75.
Sanjari Moghaddam H, Zare-Shahabadi A, Rahmani F, Rezaei N. Neurotransmission techniques in Parkinson’s illness. Rev Neurosci. 2017;28:509–36.
Tanimura A, Pancani T, Lim SAO, Tubert C, Melendez AE, Shen W, Surmeier DJ. Striatal cholinergic interneurons and Parkinson’s illness. Eur J Neurosci. 2018;47:1148–58.
Aosaki T, Miura M, Suzuki T, Nishimura Ok, Masuda M. Acetylcholine-dopamine steadiness speculation within the striatum: an replace. Geriatr Gerontol Int. 2010;10(Suppl 1):S148-157.
Maurice N, Liberge M, Jaouen F, Ztaou S, Hanini M, Camon J, Deisseroth Ok, Amalric M, Kerkerian-Le Goff L, Beurrier C. Striatal Cholinergic Interneurons Control Motor Behavior and Basal Ganglia Function in Experimental Parkinsonism. Cell Rep. 2015;13:657–66.
Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in motion issues. Trends Neurosci. 2007;30:545–53.
Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson’s illness. Neurochem Int. 2019;126:1–10.
DeMaagd G, Philip A. Parkinson’s Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T. 2015;40:668–79.
Appenzeller O, Goss JE. Autonomic deficits in Parkinson’s syndrome. Arch Neurol. 1971;24:50–7.
Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s illness: Implications for pathophysiology, prognosis, and therapy. Neurobiol Dis. 2020;134: 104700.
Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi Ok, Takahashi H. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s illness. Brain. 2008;131:642–50.
Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s illness? Neuroscience. 2008;153:733–50.
Goldstein DS, Sharabi Y, Karp BI, Bentho O, Saleem A, Pacak Ok, Eisenhofer G. Cardiac sympathetic denervation previous motor indicators in Parkinson illness. Clin Auton Res. 2007;17:118–21.
Goldstein DS. Dysautonomia in Parkinson’s illness: neurocardiological abnormalities. Lancet Neurol. 2003;2:669–76.
Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, Giordano A. MIBG scintigraphy in differential prognosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012;22:43–55.
Beaulieu J-M, Espinoza S, Gainetdinov RR. Dopamine receptors – IUPHAR Review 13. Br J Pharmacol. 2015;172:1–23.
Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson’s illness and schizophrenia. FASEB J. 1990;4:2737–44.
Kaasinen V, Ruottinen HM, Någren Ok, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson’s illness: a comparative PET examine with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41:65–70.
Farde L, Halldin C, Stone-Elander S, Sedvall G. PET evaluation of human dopamine receptor subtypes utilizing 11C-SCH 23390 and 11C-raclopride. Psychopharmacology. 1987;92(3):278–84.
Halldin C, Farde L, Barnett A, Sedvall G. Synthesis of carbon-11 labelled SCH 39166, a brand new selective dopamine D-1 receptor ligand, and preliminary PET investigations. Int J Rad Appl Instrum A. 1991;42:451–5.
Halldin C, Foged C, Chou Y-H, Karlsson P, Swahn C-G, Johan S, Sedvall G, Farde L. Carbon-11-NNC 112: A Radioligand for PET Examination of Striatal and Neocortical D<sub>1</sub>-Dopamine Receptors. J Nucl Med. 1998;39:2061.
Ekelund J, Slifstein M, Narendran R, Guillin O, Belani H, Guo N-N, Hwang Y, Hwang D-R, Abi-Dargham A, Laruelle M. In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390. Mol Imag Biol. 2007;9:117–25.
Tamagnan G, Barret O, Alagille D, Carroll V, Madonia J, Constantinescu C, SanDiego C, Papin C, Morley T, Russell D, et al. T156. In vivo characterization of the primary agonist dopamine D1 receptors PET imaging tracer [18F]MNI-968 in human. Schizophr Bull. 2018;44:1.
Ray NJ, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s sufferers with medication-induced pathological playing: a [11C] FLB-457 and PET examine. Neurobiol Dis. 2012;48:519–25.
Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B. 5-HT2 and D2 dopamine receptor occupancy within the residing human mind A PET examine with risperidone. Psychopharmacology. 1993;110:265–72.
Chefer SI, Kimes AS, Matochik JA, Horti AG, Kurian V, Shumway D, Domino EF, London ED, Mukhin AG. Estimation of D2-like receptor occupancy by dopamine within the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology. 2008;33:270–8.
Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Dollé F, Hantraye P, Kirik D. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat mannequin of Parkinson’s illness. PLoS ONE. 2014;9:e90759.
de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced adjustments in synaptic dopamine ranges improve with development of Parkinson’s illness: implications for dyskinesias. Brain. 2004;127:2747–54.
Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W. Receptor Ligands as Helping Hands to L-DOPA within the Treatment of Parkinson’s Disease. Biomolecules. 2019;9(4):142.
Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson’s illness. The Lancet. 2002;360:1767–9.
Blandini F, Armentero MT. Dopamine receptor agonists for Parkinson’s illness. Expert Opin Investig Drugs. 2014;23:387–410.
Davie CA. A evaluation of Parkinson’s illness. Br Med Bull. 2008;86:109–27.
Abbott A. Levodopa: the story to this point. Nature. 2010;466:S6–7.
Guggenheim M. Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Biological Chemistry. 1913;88:276–84.
Holtz P. Dopadecarboxylase. Naturwissenschaften. 1939;27:724–5.
Hornykiewicz O. A short historical past of levodopa. J Neurol. 2010;257:249–52.
Neurology TL. Building on 50 years of levodopa remedy. Lancet Neurol. 2016;15:1.
Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s illness: A randomized crossover examine. Mov Disord. 2017;32:283–6.
Antonini A. Levodopa within the therapy of Parkinson’s illness: an outdated drug nonetheless going sturdy. Clin Interv Aging. 2010;5:229.
Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16:1239–52.
Nutl JG, Fellman JH. Pharmacokinetics of Levodopa. Clin Neuropharmacol. 1984;7:35–50.
Hauser RA. Levodopa: Past, Present, and Future. Eur Neurol. 2009;62:1–8.
Cedarbaum JM. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clin Pharmacokinet. 1987;13:141–78.
Salat D, Tolosa E. Levodopa within the Treatment of Parkinson’s Disease: Current Status and New Developments. J Parkinson’s dis. 2013;3:255–69.
Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and medical evaluation of inhaled levodopa for OFF episodes in Parkinson’s illness. Sci Transl Med. 2016;8:360ra136.
Ellenbogen A, Stocchi F, Espay A, Poewe W, Oren S, Case R, Olanow CW. Impact of Subcutaneous Levodopa Infusion with ND0612 on Patient Reported Outcomes (4506). Neurology. 2020;94:4506.
Birnberg T, Smania G, Bjornsson M, Jonsson N, Case R, Oren S, Adar L, Karlsson M. Pharmacokinetic evaluation of levodopa and carbidopa following subcutaneous infusion: A inhabitants pharmacokinetics mannequin (2019). Neurology. 2019;2021:96.
Urso D, Chaudhuri KR, Qamar MA, Jenner P. Improving the Delivery of Levodopa in Parkinson’s Disease: A Review of Approved and Emerging Therapies. CNS Drugs. 2020;34:1149–63.
Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s illness. Drugs. 2015;75:157–74.
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in sufferers with Parkinson’s illness and end-of-dose motor fluctuations: a randomised, double-blind, managed trial. Lancet Neurol. 2016;15:154–65.
Schapira AH. Monoamine oxidase B inhibitors for the therapy of Parkinson’s illness: a evaluation of symptomatic and potential disease-modifying results. CNS Drugs. 2011;25:1061–71.
Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi Ok, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor signs of Parkinson’s illness. Mov Disord. 2011;26:S2–41.
Group PS. A managed trial of rasagiline in early Parkinson illness: the TEMPO Study. Arch Neurol. 2002;59:1937–43.
Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017;74:216–24.
Ellis JM, Fell MJ. Current approaches to the therapy of Parkinson’s Disease. Bioorg Med Chem Lett. 2017;27:4247–55.
Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: Potential for brand new therapies. Nat Rev Neurosci. 2001;2:577–88.
Lee J, Zhu W-M, Stanic D, Finkelstein DI, Horne MH, Henderson J, Lawrence AJ, O’Connor L, Tomas D, Drago J, Horne MK. Sprouting of dopamine terminals and altered dopamine launch and uptake in Parkinsonian dyskinaesia. Brain. 2008;131:1574–87.
Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor therapy of Parkinson’s illness: scientific rationale and medical implications. Lancet Neurol. 2006;5:677–87.
Antonini A, Fung VS, Boyd JT, Slevin JT, Hall C, Chatamra Ok, Eaton S, Benesh JA. Effect of levodopa-carbidopa intestinal gel on dyskinesia in superior Parkinson’s illness sufferers. Mov Disord. 2016;31:530–7.
Poewe W, Antonini A. Novel formulations and modes of supply of levodopa. Mov Disord. 2015;30:114–20.
Firnau G, Nahmias C, Garnett S. The preparation of [18F]5-fluoro-DOPA with reactor-produced fluorine-18. Int J Appl Radiat Isot. 1973;24:182–4.
Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in residing monkeys examined by positron emission tomography. Brain Res. 1983;280:169–71.
Nanni C, Fanti S, Rubello D. 18F-DOPA PET and PET/CT. J Nucl Med. 2007;48:1577–9.
Ribeiro M-J, Vidailhet M, Loc’h C, Dupel C, Nguyen JP, Ponchant M, Dollé F, Peschanski M, Hantraye P, Cesaro P, et al. Dopaminergic Function and Dopamine Transporter Binding Assessed With Positron Emission Tomography in Parkinson Disease. Arch Neurol. 2002;59:580–6.
Weeks RA, Brooks DJ. Positron emission tomography and central neurotransmitter techniques in motion issues. Fundam Clin Pharmacol. 1994;8:503–17.
Garnett ES, Firnau G, Nahmias C. Dopamine visualized within the basal ganglia of residing man. Nature. 1983;305:137–8.
Piel M, Vernaleken I, Rosch F. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem. 2014;57:9232–58.
Dhawan V, Niethammer M, Lesser M, Pappas Ok, Hellman M, Fitzpatrick T, Quartarolo L, Bjelke D, Eidelberg D, Chlay T. Prospective FDOPA PET imaging examine in human PD :our closing step in direction of NDA approval. J Nucl Med. 2020;61:1565.
Dannals RF, Neumeyer JL, Milius RA, Ravert HT, Wilson AA, Wagner HN Jr. Synthesis of a radiotracer for learning dopamine uptake websites in vivo utilizing PET: 2β-carbomethoxy-3β-(4-fluorophenyl)-[N-11C-methyl]tropane ([11C]CFT or [11C]WIN-35,428). J Labelled Compd Radiopharm. 1993;33:147–52.
Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, Oikonen V, Sonninen P, Solin O. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is decreased in early Parkinson’s illness. Synapse. 1999;31:119–24.
Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, Sörensen J. Use of 11C-PE2I PET in differential prognosis of parkinsonian issues. J Nucl Med. 2015;56:234–42.
Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC, Madras BK. [(11)C, (127)I] Altropane: a extremely selective ligand for PET imaging of dopamine transporter websites. Synapse. 2001;39:332–42.
Seifert KD, Wiener JI. The influence of DaTscan on the prognosis and administration of motion issues: A retrospective examine. Am J Neurodegener Dis. 2013;2:29–34.
Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in gentle Parkinson’s illness. Ann Neurol. 1993;34:423–31.
Piccini PP. Dopamine transporter: Basic elements and neuroimaging. Mov Disord. 2003;18:S3–8.
Brooks DJ. Molecular imaging of dopamine transporters. Ageing Res Rev. 2016;30:114–21.
Peter D, Liu Y, Sternini C, De Giorgio R, Brecha N, Edwards R. Differential expression of two vesicular monoamine transporters. J Neurosci. 1995;15:6179–88.
Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H]methoxytetrabenazine: A excessive particular exercise ligand for estimating monoaminergic neuronal integrity. Neuroscience. 1995;68:955–62.
Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson’s illness and regular growing old. Ann Neurol. 1996;40:873–84.
Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O’Keefe G, Jones G, et al. In vivo measurement of vesicular monoamine transporter kind 2 density in Parkinson illness with (18)F-AV-133. J Nucl Med. 2010;51:223–8.
Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ. Correlation of Parkinson illness severity and 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758–66.
Chaudhuri KR, Healy DG, Schapira AH. Non-motor signs of Parkinson’s illness: prognosis and administration. Lancet Neurol. 2006;5:235–45.
Politis M, Wu Ok, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson’s illness: an in vivo 11C-DASB PET examine. Neurobiol Dis. 2010;40:216–21.
Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. examine CWP: Tremor in Parkinson’s illness and serotonergic dysfunction: an 11C-WAY 100635 PET examine. Neurology. 2003;60:601–5.
Fu H, Rong J, Chen Z, Zhou J, Collier T, Liang SH. Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors. J Med Chem. 2022;65:10755–808.
Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, et al. Serotonergic pathology and illness burden within the premotor and motor part of A53T alpha-synuclein parkinsonism: a cross-sectional examine. Lancet Neurol. 2019;18:748–59.
Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson’s illness psychosis. Expert Opin Drug Discov. 2018;13:103–10.
Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson’s illness. CNS Neurol Disord: Drug Targets. 2009;8:475–91.
Crupi R, Impellizzeri D, Cuzzocrea S. Role of Metabotropic Glutamate Receptors in Neurological Disorders. Front Mol Neurosci. 2019;12:20.
Karcz-Kubicha M, Lorenz B, Danysz W. GlycineB antagonists and partial agonists in rodent fashions of Parkinson’s illness–comparability with uncompetitive N-methyl-D-aspartate receptor antagonist. Neuropharmacology. 1999;38:109–19.
Ossowska Ok. The position of excitatory amino acids in experimental fashions of Parkinson’s illness. J Neural Transm Park Dis Dement Sect. 1994;8:39–71.
Marino MJ, Valenti O, Conn PJ. Glutamate receptors and Parkinson’s illness: alternatives for intervention. Drugs Aging. 2003;20:377–97.
Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, Chase TN. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 1996;736:202–5.
Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto Ok, Yamamoto M, Hisanaga Ok, Kawamura T, Amantadine Study G. Amantadine for dyskinesias in Parkinson’s illness: a randomized managed trial. PLoS ONE. 2010;5:e15298.
Paoletti P, Neyton J. NMDA receptor subunits: perform and pharmacology. Curr Opin Pharmacol. 2007;7:39–47.
Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil within the MPTP-lesioned marmoset mannequin of Parkinson’s illness. Exp Neurol. 2000;165:136–42.
Steece-Collier Ok, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol. 2000;163:239–43.
Smart Ok, Zheng MQ, Ahmed H, Fang H, Xu Y, Cai L, Holden D, Kapinos M, Haider A, Felchner Z, et al. Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[(11)C]NR2B-Me, (R)-[(18)F]of-Me-NB1, and (S)-[(18)F]of-NB1. J Cereb Blood Flow Metab. 2022;42:1398–409.
Ahmed H, Zheng MQ, Smart Ok, Fang H, Zhang L, Emery PR, Gao H, Ropchan J, Haider A, Tamagnan G, et al. Evaluation of (rac)-, (R)- and (S)-(18)F-OF-NB1 for imaging GluN2B subunit-containing N-methyl-D-aspartate receptors in non-human primates. J Nucl Med. 2022;63(12):1912–8.
Zheng M, Ahmed H, Smart Ok, Xu Y, Holden D, Kapinos M, Felchner Z, Haider A, Tamagnan G, Carson RE, et al. Characterization in nonhuman primates of (R)-[(18)F]OF-Me-NB1 and (S)-[(18)F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. Eur J Nucl Med Mol Imaging. 2022;49:2153–62.
Rischka L, Vraka C, Pichler V, Rasul S, Nics L, Gryglewski G, Handschuh P, Murgaš M, Godbersen GM, Silberbauer LR, et al. First-in-Humans Brain PET Imaging of the GluN2B-Containing N-methyl-d-aspartate Receptor with (R)-(11)C-Me-NB1. J Nucl Med. 2022;63:936–41.
Ahmed H, Wallimann R, Haider A, Hosseini V, Gruber S, Robledo M, Nguyen TAN, Herde AM, Iten I, Keller C, et al. Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis. J Nucl Med. 2021;62:259–65.
Ahmed H, Haider A, Varisco J, Stanković M, Wallimann R, Gruber S, Iten I, Häne S, Müller Herde A, Keller C, et al. Structure-Affinity Relationships of two,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. J Med Chem. 2019;62:9450–70.
Haider A, Iten I, Ahmed H, Müller Herder A, Gruber S, Krämer SD, Keller C, Schibli R, Wünsch B, Mu L, Ametamey SM. Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. J Nucl Med. 2018;60:259–66.
Szermerski M, Börgel F, Schepmann D, Haider A, Betzel T, Ametamey SM, Wünsch B. Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies. ChemMedChem. 2018;13:1058–68.
Krämer SD, Betzel T, Mu L, Haider A, Herde AM, Boninsegni AK, Keller C, Szermerski M, Schibli R, Wünsch B, Ametamey SM. Evaluation of (11)C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. J Nucl Med. 2018;59:698–703.
Goldstein DS, Holmes C, Cannon RO, Eisenhofer G, Kopin IJ. Sympathetic Cardioneuropathy in Dysautonomias. N Engl J Med. 1997;336:696–702.
Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson’s illness: A evaluation. Parkinsonism Relat Disord. 2014;20:267–73.
De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease. JAMA Neurol. 2017;74:970–6.
De Pablo-Fernandez E, Warner TT. Autonomic Dysfunction in Parkinson’s Disease: The Hidden Game Changer? Mov Disord. 2018;33:1028.
Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH. Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol. 2016;39:220–6.
Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson’s illness from a number of system atrophy. Neurology. 1999;53:1020–5.
Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s illness and associated issues. Mov Disord. 2009;24(Suppl 2):S732-741.
